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Background: The purpose of this study was to evaluate the efficacy of vildagliptin 
50 mg once daily in patients with severe renal impairment (estimated glomerular filtration 
rate , 30 mL/min/1.73 m2) and longstanding type 2 diabetes not adequately controlled with 
insulin therapy, which is a difficult-to-treat population, with limited therapeutic options and a 
high susceptibility to hypoglycemia.
Methods: This was a post hoc subanalysis of data obtained during a previously described 
randomized, double-blind, parallel-group, 24-week study comparing the efficacy and safety of 
vildagliptin 50 mg once daily versus placebo in patients with type 2 diabetes and moderate or 
severe renal impairment. The present data derive from 178 patients with severe renal impairment 
(baseline estimated glomerular filtration rate approximately 21 mL/min/1.73 m2, 100 randomized 
to vildagliptin, 78 randomized to placebo), all of whom were receiving insulin therapy (alone 
or in combination with an oral antidiabetic agent) for longstanding type 2 diabetes (mean 
approximately 19 years).
Results: With vildagliptin in combination with insulin, the adjusted mean change (AM∆) in 
HbA
1c
 from baseline (7.7% ± 0.1%) was −0.9% ± 0.4% and the between-treatment difference 
(vildagliptin – placebo) was −0.6% ± 0.2% (P , 0.001). The percentage of patients achieving 
endpoint HbA
1c
 , 7.0% was significantly higher with vildagliptin than placebo (45.2% 
versus 22.8%, P = 0.008). When added to insulin, vildagliptin and placebo had comparable 
hypoglycemic profiles and did not cause weight gain. Both treatments were similarly well 
tolerated, with comparable incidences of adverse events, serious adverse events, and deaths.
Conclusion: When added to insulin therapy in patients with severe renal impairment and 
longstanding type 2 diabetes, vildagliptin 50 mg once daily was efficacious, eliciting HbA
1c
 
reductions consistent with those previously reported for a patient population with much more 
recent onset of type 2 diabetes and normal renal function, and had a hypoglycemic profile 
comparable with placebo. Accordingly, vildagliptin is a suitable treatment option for patients 
with advanced type 2 diabetes and impaired renal function who require insulin therapy and 
present a serious therapeutic challenge in clinical practice.
Keywords: chronic kidney disease, antidiabetic drug, dipeptidyl peptidase-4 inhibitor, 
glucagon-like peptide-1, type 2 diabetes
Introduction
Chronic kidney disease is a common complication in patients with diabetes,1 and 
hyperglycemia in patients with renal impairment is difficult to manage due to the 
limited therapeutic options and high prevalence of comorbidities.2–4 Longstanding type 
2 diabetes in patients with advanced kidney disease often requires insulin therapy.5,6 
Insulin dosage is a real challenge in a renally impaired population due to impaired 
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catabolism and clearance of insulin. The renal clearance of 
insulin shows little change if the glomerular filtration rate 
(GFR) is above 40 mL/min, but it falls precipitously with 
further progression of chronic kidney disease, especially when 
GFR is less than 15–20 mL/min.7 The subsequent difficulty 
with insulin dose selection increases the risk of hypoglycemia, 
which is already a limiting factor in the maintenance of good 
glycemic control in patients receiving insulin8 and is further 
exacerbated by renal impairment.9,10 Thus, patients with 
severe renal impairment and type 2 diabetes inadequately 
controlled with insulin comprise a growing population with 
an unmet medical need for new therapies that lower blood 
glucose without increasing the risk of hypoglycemia.11
Vildagliptin is a dipeptidyl peptidase-4 inhibitor that 
blocks the inactivation of glucagon-like peptide-1 and 
glucose-dependent insulinotropic polypeptide, thus raising 
plasma concentrations of the intact, active form of these 
peptides and thereby improving islet function by increasing 
α-cell and β-cell sensitivity to glucose.12,13 In patients with 
type 2 diabetes and normal renal function (or mild renal 
impairment) vildagliptin is effective as monotherapy14–18 and 
in combination with a variety of antidiabetic drugs.19–25 In all 
of these studies, vildagliptin has consistently evinced a low 
hypoglycemic potential, including in patients with advanced 
type 2 diabetes who required insulin therapy.
The efficacy and safety of vildagliptin 50 mg once 
daily was also recently demonstrated in patients with 
moderate or severe renal impairment both after 24 weeks26 
and one year of treatment.27 In the aforementioned study,26 
80% of patients with severe renal impairment (estimated 
GFR , 30 mL/min/1.73 m2) had inadequate glycemic control 
while receiving insulin therapy at baseline, reflecting the 
limited therapeutic options in this population, and providing 
a unique opportunity to examine the question of whether 
vildagliptin in combination with insulin was also efficacious, 
with a low hypoglycemic potential in patients with severe 
renal impairment, as it is in patients with less advanced type 2 
diabetes and normal renal function. Accordingly, the present 
analysis was performed to assess the effects of vildagliptin 
in the subgroup of patients with advanced type 2 diabetes 
and severe renal impairment whose hyperglycemia was not 
adequately controlled with insulin alone or in combination 
with an oral antidiabetic agent at baseline.
Materials and methods
This is a post hoc subanalysis of data from a previously 
described randomized, double-blind, parallel-group, 
placebo-controlled, 24-week clinical trial assessing the 
efficacy and safety of vildagliptin 50 mg once daily in 
patients with type 2 diabetes and moderate (n = 294) or 
severe (n = 221) renal impairment. The key entry criteria 
for the aforementioned trial included age 18–85 years, HbA
1c
 
6.5%–10%, and body mass index 18–42 kg/m2. After a 
2-week single-blind, placebo run-in period, eligible patients 
were randomized (week 0, baseline) to vildagliptin 50 mg 
once daily or placebo, and study visits occurred at 4-week 
intervals from week 4 to week 24. The detailed methodology 
of this study has been described previously.26
The present data analysis includes only patients with 
severe renal impairment (estimated GFR by the Modification 
of Diet in Renal Disease formula , 30 mL/min/1.73 m2). 
Further, inclusion in this analysis required that patients 
were receiving ongoing insulin therapy, either alone, 
or in combination with an oral antidiabetic agent (ie, a 
sulfonylurea, meglitinide, or a thiazolidinedione), resulting 
in 178 patients contributing to the subanalysis.
Baseline insulin dose regimens were recorded, as were all 
major changes in insulin therapy (ie, increases or decreases 
in dose of .20% of the baseline dose, or change of insulin 
type or addition of another insulin type). The mean insulin 
doses at baseline and endpoint were calculated from these 
records. Intensification of insulin therapy by increasing 
insulin dose . 20% or adding a new type(s) of insulin was 
defined as initiating rescue medication.
Study assessments
HbA
1c
 and fasting plasma glucose were assessed at all study 
visits. Responder analysis was also performed as described 
below. Hypoglycemia was defined as symptoms suggestive 
of low blood glucose confirmed by self-monitored blood 
glucose measurement , 3.1 mmol/L plasma glucose 
equivalent. Severe hypoglycemia was defined as any episode 
requiring assistance of another party (whether or not a 
confirmatory self-monitored blood glucose measurement was 
available). All adverse events were recorded and assessed 
by the investigator for severity and possible relationship to 
study medication.
Statistical analysis
The adjusted mean changes (AM∆) in HbA
1c
 and fasting 
plasma glucose from baseline to rescue-censored endpoint 
(with final observation carried forward for data censored 
at initiation of rescue medication) were compared between 
treatments using an analysis of covariance model with 
baseline value as covariate and background therapy, pooled 
center, and treatment as factors. A similar model (without 
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background therapy as a factor) was used to determine 
AM∆ HbA
1c
 for patients with baseline HbA
1c
 . 8.0% and 
baseline HbA
1c
 . 9.0%. Responder rates (percentage of 
patients with baseline HbA
1c
 $ 7.0% achieving endpoint 
HbA
1c
 , 7.0%) were assessed by treatment and compared by 
Chi-square test. Body weight, hypoglycemia, and safety data 
were summarized descriptively by treatment. Body weight 
and safety analyses were performed on all data collected, 
regardless of rescue medication use.
Results
Of the 221 patients with severe renal impairment randomized 
in the trial, 178 patients (100 in the vildagliptin group and 
78 in the placebo group) were receiving insulin treatment at 
baseline. Table 1 summarizes the baseline demographic and 
background characteristics in the randomized population. 
These insulin-treated patients with severe renal impairment 
had a mean age of 64 years (with over half of the 
participants $ 65 years of age), mean HbA
1c
 of 7.7%, mean 
estimated GFR of approximately 21 mL/min/1.73 m2 and 
mean body mass index of 30 kg/m2. They had longstanding 
type 2 diabetes (mean duration of known type 2 diabetes 
was about 19 years), with a mean duration of insulin use 
of about 5 years. The majority of patients were receiving 
basal insulin at baseline, alone or in a basal/bolus regimen. 
The mean insulin dose at baseline was approximately 
53 U/day in patients randomized to vildagliptin and about 
50 U/day in those randomized to placebo, and did not change 
meaningfully in either group during the study. Fewer than 
15% of patients were receiving an oral antidiabetic agent in 
addition to insulin, primarily sulfonylureas. The treatment 
groups were generally well balanced with respect to baseline 
characteristics.
Figure 1 depicts the time course of mean HbA
1c
 during 
24 weeks of treatment with vildagliptin 50 mg once daily or 
placebo added to prior insulin therapy. HbA
1c
 values were 
consistently lower in the vildagliptin compared with the 
placebo group at all post-baseline visits. In the vildagliptin 
group, the AM∆ HbA
1c
 from baseline (7.7% ± 0.1%) to 
endpoint was −0.9% ± 0.4%, while in the placebo group 
baseline HbA
1c
 averaged 7.8% ± 0.1% and the AM∆ 
was −0.3% ± 0.4%. The between-treatment difference in 
AM∆ HbA
1c
 (vildagliptin – placebo) was −0.6% ± 0.2% 
(P , 0.001).
The percentage of patients (with baseline HbA
1c
 $ 7.0%) 
achieving endpoint HbA
1c
 , 7.0% in the vildagliptin group 
(33/73 patients, 45.2%) was twice that in the placebo group 
(13/57 patients, 22.8%, P = 0.008). Further, in patients with 
high baseline HbA
1c
 . 8.0%, the absolute reduction in HbA
1c
 
with vildagliptin (baseline 9.0%, AM∆ −1.4% ± 0.3%, n = 30) 
was greater than in the overall study population, while 
there was a minor decrease with placebo (baseline 8.9%, 
AM∆ −0.2% ± 0.3%, n = 29), resulting in a between-group 
difference in AM∆ (vildagliptin – placebo) of −1.1% ± 0.3% 
(P = 0.001). In patients with baseline HbA
1c
 . 9.0%, the 
decrease in HbA
1c
 with vildagliptin was still larger (baseline 
HbA
1c
 9.5%, n = 15, AM∆ HbA
1c
 −1.8% ± 0.5%), as was the 
between-treatment difference (−2.2% ± 0.7%, P = 0.008).
Fasting plasma glucose also decreased with vildagliptin 
plus insulin treatment. Baseline fasting plasma glucose 
averaged 8.1 ± 0.3 mmol/L in the vildagliptin group, and 
the AM∆ fasting plasma glucose was −2.4 ± 1.1 mmol/L. 
The between-treatment difference was −0.8 ± 0.4 mmol/L; 
however, this did not achieve statistical signif icance 
(P = 0.063).
The hypoglycemia profile was generally similar between 
vildagliptin and placebo when added to insulin. In the 
Table 1 Patient baseline demographic and background 
characteristics by treatment (randomized population)
Mean ± SD or n (%) Vildagliptin  
50 mg once  
daily (n = 100)
Placebo  
(n = 78)
Demographic variable or background characteristic*
Mean age (years) 64.1 ± 9.0 64.9 ± 11.3
Age group $ 65 years 53 (53.0) 41 (52.6)
Gender, male 51 (51.0) 41 (52.6)
Race 
 European 
 Hispanic or Latino 
 Asian 
 Other
 
49 (49.0) 
31 (31.0) 
17 (17.0) 
3 (3.0)
 
40 (51.3) 
21 (26.9) 
16 (20.5) 
1 (1.3)
Mean eGFR (mL/min/1.73 m2) 21.7 ± 5.6 20.6 ± 6.7 
Mean BMI (kg/m2) 
 BMI $ 30 kg/m2
30.8 ± 5.8 
53 (53.0)
29.6 ± 5.0 
35 (44.9)
Mean HbA1c (%) 
 HbA1c . 8.0%; n (%) 
 HbA1c . 9.0%; n (%)
7.7 ± 1.0 
30 (30.0) 
15 (15.0)
7.7 ± 1.1 
29 (37.2) 
11 (14.1)
Mean FPG (mmol/L) 8.1 ± 2.8 8.5 ± 3.5
Mean duration of T2DM (years) 18.8 ± 8.3 20.2 ± 9.5
Antidiabetic therapy at BL, n (%) 
 Insulin monotherapy 
 Insulin + OAD(s) 
 Insulin + SU
 
87 (87.0) 
13 (13.0) 
11 (11.0)
 
66 (84.6) 
12 (15.4) 
5 (6.4)
Mean insulin dose at baseline (U/day) 53.1 ± 35.9 49.6 ± 41.6
Mean duration of insulin use (years) 5.3 ± 5.9 5.2 ± 6.4
Note: *There were no significant between-group differences in any baseline 
characteristic. 
Abbreviations: BL, baseline; BMI, body mass index; GFR, glomerular filtration 
rate; HbA1c, glycosylated hemoglobin; T2DM, type 2 diabetes mellitus; OAD, oral 
antidiabetic agent; SD, standard deviation; SU, sulfonylurea; FPG, fasting plasma 
glucose.
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vildagliptin group, 19/100 patients (19.0%) experienced 
a total of 36 hypoglycemic events. In the placebo group, 
11/78 patients (14.1%) experienced a total of 36 hypoglycemic 
events. Thus, in the placebo group, of the patients reporting 
any hypoglycemic event, a higher percentage reported 
two or more events (72.7% with placebo versus 47.4% 
with vildagliptin). Severe hypoglycemia was reported at a 
similarly low rate in the two groups (2.0% with vildagliptin 
and 2.6% with placebo).
Body weight remained constant in the vildagliptin group; 
baseline body weight averaged 82.2 ± 1.9 kg and the mean 
body weight at week 24 was 82.1 ± 2.2 kg. In the placebo 
group, baseline body weight was 78.7 ± 1.7 kg and at week 
24 body weight averaged 79.4 ± 1.9 kg.
The overall adverse event profile was also similar in the 
two treatment groups, and there were no notable differences 
in the subgroup of insulin-treated patients with severe renal 
impairment compared with the overall study population that 
was previously reported. The percentage of patients receiving 
vildagliptin in combination with insulin and experiencing 
one or more adverse event, severe adverse event, or adverse 
event leading to discontinuation were 79.0%, 19.0%, and 
10.0%, respectively. The corresponding percentages for the 
placebo plus insulin group were 76.9%, 24.4% and 6.4%, 
respectively. Apart from hypoglycemia, the most common 
specific adverse events were edema, hyperhidrosis, and 
dizziness. They were reported by similar percentages of 
patients in the vildagliptin and placebo groups. Two patients 
receiving vildagliptin (2.0%) and four patients receiving 
placebo (5.1%) died during the study: none of the deaths 
were suspected to be related to study medication.
There was no deterioration of renal function in either 
group after 24 weeks of treatment. The mean estimated GFRs 
at baseline were 21.8 ± 0.5 and 20.7 ± 0.8 mL/min/1.73 m2 
in the vildagliptin and placebo group, respectively, and were 
20.9 ± 0.7 and 19.3 ± 1.1 mL/min/1.73 m2 at week 24.
Discussion
As mentioned in detail previously, patients with severe renal 
impairment and advanced type 2 diabetes requiring insulin 
therapy comprise a difficult-to-treat patient population with a 
high propensity for hypoglycemia. The main findings of the 
present subanalysis of data from such a population were that 
vildagliptin added to insulin markedly improved glycemic 
control and had a hypoglycemic profile similar to placebo.
The magnitude of the glucose-lowering seen in this sub-
group (HbA
1c
 reduction 0.9% from baseline of 7.7%) was in 
the range seen previously in studies of vildagliptin monother-
apy and combination therapy in patients with a much shorter 
history of type 2 diabetes and normal renal function.19,28,29 
Relative to placebo added to insulin, the decrease in HbA
1c
 
with vildagliptin added to insulin (−0.6%) was clinically 
meaningful. As expected, the magnitude of reduction in HbA
1c
 
and the between-treatment difference was larger in patients 
6.6
7.0
7.4
7.8
8.2
–2 BL 4 8 12 16 20 24
Time (wk)
M
ea
n
 A
1C
 (
%
)
Vildagliptin 50 mg qd
Placebo
Figure 1 Time course of mean HbA1c in patients with severe renal impairment receiving insulin therapy. 
Notes: Mean ± standard error. n for vildagliptin group at baseline and week 24 = 99 and 81 patients, respectively; n for placebo group at baseline and week 24 = 77 and 59, 
respectively.
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with higher baseline HbA
1c
  levels. Thus, the β-cell dysfunc-
tion and other metabolic derangements attendant with severe 
renal impairment2 and longstanding type 2 diabetes requiring 
insulin therapy10 clearly did not mitigate the efficacy or the 
low hypoglycemic potential of vildagliptin.
The fasting plasma glucose decreased modestly and the 
AM∆ fasting plasma glucose was not significantly different 
from placebo. This likely reflects the fact that the majority 
of patients were receiving basal insulin prior to intervention, 
and this form of therapy itself reduces the contribution of 
fasting plasma glucose to overall glycemic exposure (as 
reflected by HbA
1c
).30
Generally, an improvement in glycemic control in the range 
found in the present analysis, with nearly half of the patients 
achieving target HbA
1c
 , 7%, is expected to be associated with 
a marked increase in hypoglycemia, particularly in patients 
with longstanding disease requiring insulin.31–33 Therefore, 
the finding that there was no overall increase in hypoglycemia 
with vildagliptin despite a clinically meaningful decrease 
in HbA
1c
 is notable. While there was a slight increase in 
the number of patients experiencing hypoglycemic events 
with vildagliptin added to insulin (19.0% versus 14.1% with 
placebo), the number of hypoglycemic episodes was identical 
with vildagliptin (36 episodes/100 patients) and placebo 
(36 episodes/78 patients), and there was a similarly low 
risk of severe hypoglycemia (2.0% with vildagliptin versus 
2.6% with placebo). Thus, the question arises of how such 
glucose-lowering occurs without increased hypoglycemia, 
as shown in the present analysis with vildagliptin added to 
insulin. A possible explanation is that vildagliptin enhances 
the counter-regulatory response to incipient hypoglycemia, 
which is greatly impaired in insulin-dependent patients 
with type 2 diabetes, who have more progressive damage of 
pancreatic islets compared with patients with less advanced 
type 2 diabetes and treated with oral antidiabetic agents.10
An effect of vildagliptin on glucagon counter-regulation 
during hypoglycemia in drug-naïve patients with type 2 
diabetes was indeed demonstrated in a mechanistic study 
examining the glucagon response to hypoglycemia in patients 
with type 2 diabetes using stepped hypoglycemic clamps.13 
In that study, the increase in glucagon that occurred during 
the hypoglycemic clamp step at 2.5 mmol/L was significantly 
greater in vildagliptin-treated patients than in placebo-treated 
patients, representing a 38% increase with vildagliptin. 
This is likely due to the glucose-dependent nature of the 
effects of glucagon-like peptide-1 and glucose-dependent 
insulinotropic polypeptide on insulin34,35 and glucagon36–38 
secretion, through which vildagliptin acts.
In addition to the present subanalysis of vildagliptin 
added to insulin in patients with severe renal impairment, 
there are two previous clinical studies of vildagliptin added 
to insulin in patients with normal renal function or mild 
renal impairment. In the first such study, by Fonseca et al24 
in patients on high doses of insulin (.80 U/day) and 
multiple injections of short-acting insulin(s), addition of 
vildagliptin significantly decreased both the frequency and 
severity of hypoglycemia relative to placebo plus insulin, 
while producing a modest improvement in glycemic control 
(−0.3% relative to placebo). In a recent 24-week, placebo-
controlled study by Kothny et al,25 vildagliptin added to 
basal or premixed insulin (about 40 U/day) with or without 
metformin elicited a marked improvement in glycemic 
control (−0.7% relative to placebo), with no increase in the 
incidence of hypoglycemia compared with placebo added 
to insulin (8.4% versus 7.2%, respectively). The reduction 
in incidence of hypoglycemia in the earlier study24 could be 
potentially explained by the improved counter-regulation with 
vildagliptin, which not only prevents hypoglycemia when the 
glucose level drops, but also can reduce hypoglycemia when 
the underlying incidence and severity of this complication is 
already high. A higher underlying incidence of hypoglycemia 
and more modest glucose-lowering effect seen in the earlier 
study compared with the study by Kothny et al and our 
present analysis are likely due to differences in the insulin 
regimens utilized in these studies, which reflect the changes 
in the treatment paradigm of insulin therapy in type 2 diabetes 
towards predominant use of basal insulin (with or without 
metformin)39 versus short-acting insulin in the past.
An alternative to adding vildagliptin to ongoing 
insulin therapy in patients with severe renal impairment 
and type 2 diabetes could be simply to increase the dose 
of insulin employed, or add another type of insulin to the 
regimen. However, it is well known that hypoglycemia is 
the limiting factor in managing diabetes with insulin,40,41 
especially in patients with renal impairment who actually 
require a reduction of the insulin dose with the progression 
of renal impairment.10 Accordingly, it may be assumed that 
increasing the insulin dose would substantially increase the 
frequency of hypoglycemia. The present study was designed 
to assess the efficacy of vildagliptin added to stable, existing 
type 2 diabetes therapy in patients with renal impairment, 
and therefore cannot address how vildagliptin would compare 
with insulin intensification. Nonetheless, a confirmative 
noninferiority study where vildagliptin is compared with 
intensification of insulin treatment could be an important 
follow-up to the current work.
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The general safety and tolerability of vildagliptin in 
patients with severe renal impairment was addressed in detail 
previously26,27 and, not surprisingly, no new safety signals 
were identified in the present subanalysis.
In conclusion, the present substudy confirms that 
vildagliptin is a suitable therapeutic option for patients with 
declining renal function and advanced type 2 diabetes who 
require insulin treatment. When added to insulin therapy in 
patients with severe renal impairment and longstanding type 
2 diabetes, vildagliptin 50 mg once daily was efficacious 
and well tolerated, without increasing the risk or severity 
of hypoglycemic episodes, without weight gain, and with 
HbA
1c
 reductions consistent with those previously reported 
in patients with much more recent onset of type 2 diabetes 
and normal renal function.
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